ARCA Biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. Special Protocol Assessment also known as SPA is an agreement with the FDA that the proposed trial protocol design, clinical endpoints and statistical analyses are acceptable to support regulatory approval.

Announcing about the submission of this SPA, CEO and President of ARCA Biopharma, Michael Bristow said that the submission of their trial protocol for review under the FDA’s SPA process is an important milestone for ARCA as well as for Gencaro and that they believe that Gencaro has the potential to provide a needed advancement in the treatment of patients with chronic heart failure, a disease afflicting approximately 6 million people in the United States of America.

Xcorporeal is a medical device company that has been engaged in developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs. As per the agreement the Purchaser will pay royalties to the Seller during the life of the patents included in the HD WAK Technology being transferred to the Purchaser, as well as the royalties to the Sellers during the life of the patents included in the supersorbent technology being transferred to the Purchaser. The Purchaser also granted the Sellers an option to obtain a perpetual, worldwide license to the supersorbent technology in healthcare fields other than renal, in exchange for certain consideration to be paid to the Purchaser in the event of the exercise of the option.

Arrowhead Research Corporation is a nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is seeking to build value for shareholders through the progress of majority-owned subsidiaries and minority investments commercializing nanotech products and applications. Talking about these new funds, President and CEO of Arrowhead, Christopher Anzalone said that this capital infusion will help them to put a solid footing in 2010 and these funds will provide the resources to continue Calando’s clinical study as well. He also further mentioned that the preliminary results of Calando study are encouraging and that expect the value of Calando’s drug candidate and proprietary RNAi delivery system will help them. He further stated that funds from this financing will also be used to explore other exciting new prospects in the nanobiotech space where they still see more opportunities to enhance their portfolio and create additional shareholder value.

@@AdsenseRight@@ ProtoKinetix Inc is one of the leading biopharmaceutical companies that have been into the development of medicines for many biotechnology and cosmetics industries. The Company has also patented a family of synthetic anti-aging glycoproteins (AAGP). Currently, the Company is in dialogue with many major corporations and institutions that have approached ProtoKinetix with a series of proposals about the broad range of applications for AAGP products. CEO and President of ProtoKinetix, Ross Senior, said that the proposals are currently being evaluated and that they are happy the Company has received a number of excellent opportunities to enter into new collaborations which will help them expand the use and applications of their AAGP technology.

He further mentioned that they will soon declare the results of their evaluations and that such European collaborations and proposals will surely give them more confidence to be successful both scientifically and financially. The AAGP technology used by ProtoKinetix has been successfully evaluated in laboratories in France and University of Bordeaux which proved that the molecules were non-toxic in standard concentrations.

@@Adsense@@ Advaxis Inc is a New Jersey-based pharmaceutical company that is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer. The reason Advaxis is working on this research because as per the survey HPV is the most prevalent sexually transmitted disease in the US and the cause of cervix cancer, 40% of head and neck cancer, as well as penile, vulvar and anal cancer.

In the Phase 1 clinical trial, Advaxis has found that multiple doses of the agent were safely administered to this patient population at two (2) different dose levels and that the side effect profile, comprised of a flu-like syndrome, was consistent with strong immune stimulation. The Phase II trial will be conducted by GOG investigators and largely underwritten by the NCI and together both the teams will investigate greater statistical power of this vaccine.

@@AdsenseRight@@ In October 2009, GTx received a Complete Response Letter from the United States Food and Drug Administration regarding its NDA for toremifene 80 mg. GTx has licensed to Ipsen Developments Limited exclusive rights to develop and commercialize in the European Union, Switzerland, Norway, Iceland, Lichtenstein, and the Commonwealth of Independent States. The Company has also undergone an agreement with Merck for the development of new class of drugs. However, so far the FDA has not responded and GTx sales were affected badly because of the delay. The Company has decided to reduce around 28 percent of their current workforce immediately. However, employees who have been affected by this situation will continue to receive severance pay and medical benefits. CEO of GTx, Dr. Mitchell Steiner said that it was the delay in the commercialization of toremifene 80 mg that has forced them to take such odd decisions and that they appreciate the contributions of each and every employee.

@@AdsenseRight@@ Previously released data shows, that with the use of Augment, patients can expect a comparable treatment outcome while being spared the pain and potential morbidity associated with traditional autograft bone harvesting and transplantation. Augment is a completely synthetic grafting system for bone regeneration and is composed of a purified recombinant growth factor, recombinant human platelet derived growth factor (rhPDGF-BB), and a synthetic calcium phosphate matrix, beta-tricalcium phosphate (β-TCP). The combination of the two components of Augment is the key to the overall effectiveness of the product.

BioMimetic Therapeutics is one of the leading biotechnology companies utilizing purified recombinant human platelet-derived growth factor (rhPDGF-BB) in combination with tissue specific matrices as its primary technology platform for promotion of tissue healing and regeneration. The Company has completed and ongoing clinical trials with its product candidates Augment and Augment Injectable in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. BioMimetics Therapeutics’ COO, Steven Hirsch said that they are really excited about the shipment and sale of Augment Bone Graft to Canada which would be their first commercial success and opportunity within orthopedics.

@@AdsenseRight@@ Fero Industries is planning to grow through acquisition strategy for 2010 and they have already begun the initial negotiations with Pyro Pharmaceuticals. Fero also intends to take advantage of Pyro’s acquisition by mixing Pyro’s world class management team and future acquisitions for the growth of the companies both horizontally and vertically with strategic and synergistic acquisition targets which will be announced when certain milestones are reached for this merger.

Another reason why Fero Industries have gone for the acquisition is because of Pyro’s management and board members who have extensively public company experience and because they have successfully handled acquisitions and joint ventures with various large companies. In the past Pyro has attracted impressive number of pharmaceutical companies like Merck, Glaxo, Abbott, Bristol-Myers Squibb and Cubist Pharmaceuticals and many others.

@@AdsenseRight@@ In the middle of this year, Medifocus announced that Health Canada had granted full ITA approval to allow the initiation of Medifocus’ pivotal phase III clinical trial on focused heat treatment of breast cancer. Later they filed a comprehensive Investigational Device Exemption (IDE) application with the FDA to obtain clearance for the same microwave system in the United States. The focused heat treatment provided by the Company’s APA 1000 system, once commercialized, should in a position to help those patients who desire breast conservation by significantly improving their chance of attaining the desired tumor shrinkage to avoid a mastectomy. CEO and Chairman of Medifocus, Dr. Augustine Cheung said that clearance from the FDA about their IDE will be a significant milestone for Medifocus to work towards the globalization of this thermotherapy system.

@@AdsenseRight@@ Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. The Phase 3 trial was designed to determine the accuracy of Lymphoseek to identify lymphatic tissue as compared to commonly used vital blue dyes. The primary objective of the Phase 3 was to obtain at least 203 lymph nodes identified with the vital blue dyes and to statistically demonstrate that 94% of those nodes were identified with Lymphoseek. Neoprobe’s CEO and President, David Bupp mentioned that the filing of the end-of-Phase 3 report is an important milestone in the development process for Lymphoseek and that they are very pleased with the final results of the Phase 3 trial and we look forward to meeting with FDA to discuss further plans.